Norway· NO-ID_B8E199C1-E91A-4AF4-84F6-201F87A51C20
Fiasp
A insulin aspart product containing insulin aspart, registered in Norway by Novo Nordisk A/S (2). The same ATC class is registered in 11 of our 19 countries.
Checked against FEST (Norway) on
Informational only — not a medical device.
Where it is registered
Insulin aspart is registered in 11 of 19 countries.
Countries holding a registration under ATC A10AB05 (insulin aspart), each read from that country’s own register.
- This record: Norway, from FEST (Norway)
- 7 of them publish a price we can compare per daily dose
Insulin aspart · ATC A10AB05
11 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Ireland
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
The record
At a glance
FEST (Norway)- Active substance
- Insulin Aspart
- Manufacturer
- Novo Nordisk A/S (2)
- Country
- Norway (NO)
- ATC code
- A10AB05
- ATC class
- Insulin aspart
- Defined daily dose
- 40 E, P
- Reimbursed
- Not published by this register
- Source register
- FEST (Norway)
- Last checked
- September 25, 2026
Packs & prices · 3
1 priced- no_merkevare_idID_B8E199C1-E91A-4AF4-84F6-201F87A51C20
- no_varenummer5225195 x 3NOK 361
- gtin5712249102708
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
434 interactions on record for insulin aspart.
Graded by severity as the source publishes them — 15 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Insulin aspart · interactions on record
434 records
- 15 severe
- 368 moderate
- 50 minor
Most severe, free to view
- SucralfateA02BX02moderate
- ThiethylperazinA04AB03moderate
- TriflupromazinA04AD06moderate
- PrednisoloneA07EA01moderate
1 more interaction with mechanism and management, from a commercially licensed source.
Sign in to check- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Insulin aspart in 16 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- CzechiaDAZPARDAGan & Lee Pharmaceuticals Europe GmbH, Düsseldorf
- United KingdomFiasp 100units/ml solution for injection 10ml vialsNovo Nordisk Ltd
- United States.Insulin Aspart Protamine and Insulin AspartA-S Medication Solutions
- BelgiumDazparda 100 U/mlGan & Lee Pharmaceuticals Europe
- FinlandDazpardaGan & Lee Pharmaceuticals Europe GmbH
- SwedenDazparda 100 E/ml Injektionsvätska, lösning i förfylld injektionspennaGan & Lee Pharmaceuticals Europe GmbH
- IcelandFiaspNovo Nordisk A/S*
- PolandDazpardaGan & Lee Pharmaceuticals Europe GmbH
Authorised across Europe · EMA
The same active substance is authorised in 2 EEA countries. Names it is sold under:
- Iceland · Dazparda, Fiasp
- Liechtenstein · Dazparda, Insulin Aspart Sanofi
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of FEST (Norway). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/0602f339-4d36-4da4-868e-613882aa3e66 GET /v1/drugs/0602f339-4d36-4da4-868e-613882aa3e66?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Injeksjonsvæske, oppløsning",
"source": "fest",
"status": "A",
"atc_name": "Insulin aspart",
"merkevare_id": "ID_B8E199C1-E91A-4AF4-84F6-201F87A51C20",
"name_form_strength": "Fiasp inj, oppl 100 E/ml",
"prescription_group": "C"
}See everything about insulin aspart.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.